HomeSpinal Cord Diseases or DisordersMultiple sclerosisMS Coalition-Disease Modifying Therapy

9.5. MS Coalition-Disease Modifying Therapy

Please see the attached MS Coalition Disease Modifying Therapy paper. And, visit MS Coalition for more details.

MS Coalition
3 University Plaza Drive, Suite 116
Hackensack, NJ 07601
Phone: (201)489-0540
Fax: (862) 772-7275


The National MS Society and the other member organizations of the MS Coalition have collaborated to produce a consensus document to summarize current evidence about disease modification and provide support for broad access to FDA-approved DMTs. This evidence-based document may be useful when addressing insurance questions (preauthorization, formulary, etc.); a companion piece for general audiences is currently under development.

After extensive review of the evidence, the MS Coalition makes the following recommendations:


Initiation of treatment with an FDA-approved DMT is recommended:

Treatment with any given DMT should be continued indefinitely unless any of the following occur:

The factors affecting choice of treatment are complex and most appropriately addressed by the individual in collaboration with the treating clinician. Movement from one DMT to another should occur only for medically appropriate reasons.


Due to significant variability in the MS population, people with MS and their clinicians require full access to a range of treatment options:

Access to treatment should not be limited by the patient's frequency of relapses, level of disability, age, gender or ethnicity. Absence of relapses while on treatment should not be considered a justification for discontinuation of treatment. Treatment should not be discontinued to allow for determination of coverage by payers.


This page was: Helpful | Not Helpful